Stocks
Processa Pharmaceuticals, Inc.PCSA
NASDAQHealthcareBiotechnology$1.79
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing next-generation chemotherapies for rare and orphan oncology indications. Its lead candidate, PCS6422, is designed to improve the safety and efficacy of existing cancer drugs by targeting metabolic pathways. Investors track the stock for its pipeline progress and upcoming clinical trial data.
52W Range: $1.04-$10.85
Congressional Interest in Processa Pharmaceuticals, Inc. (PCSA)
No congressional trades have been disclosed for Processa Pharmaceuticals, Inc. (PCSA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PCSA?
No congressional trades found for this stock.